SEC Filing Analysis: Artiva Biotherapeutics, Inc. (ARTV)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The President and CEO, Fred Aslan, conducted a small, pre-planned sale of common stock, accompanied by a separate share withholding for tax purposes. The total value and size are immaterial relative to the company's market capitalization.
• Market Impact: Neutral. The sale was executed under a Rule 10b5-1 plan, indicating it was not based on immediate, non-public information. The transaction size is too small to influence market sentiment.

Company Information

Field	Value
Company	Artiva Biotherapeutics, Inc.
Ticker Symbol	ARTV
CIK	0001817241
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	Aslan Fred
CIK	0001909362
Title/Position	President and CEO
Relationship	Director, Officer

Transaction Details

This filing reports two dispositions. The primary market transaction is detailed below.

Field	Value
Form Type	4
Transaction Date	2025-11-17
Transaction Code	S (Open market sale)
Security Type	Common Stock
Shares Involved	6,375
Price Per Share	$3.376 (Weighted Avg.)
Total Value	$21,522
Shares Owned After	343,999
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$21,522
% of Market Cap	0.027%
Shares Transacted	6,375
% of Shares Outstanding	Not Available
Post-Transaction Ownership	343,999 shares
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: Artiva Biotherapeutics has a market capitalization of approximately $80 million. The sale of $21,522 represents a negligible 0.027% of the company's total market value, falling far below the 0.1% threshold for even low significance.
• Ownership Concentration: The sale represents a very small fraction (approx. 1.8%) of the CEO's direct holdings prior to the sale, indicating no significant change in his stake.
• Transaction Significance: The transaction is rated as 'Low' significance due to its small value relative to the company's market cap and the fact that it was executed under a pre-arranged 10b5-1 trading plan.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Pre-scheduled sales under 10b5-1 plans are generally not considered strong indicators of an insider's current outlook. The small size of the transaction further reinforces its neutral impact.

Volume & Sentiment

• Expected Volume Impact: None. The transaction size is too small to have a noticeable effect on trading volume.
• Sentiment Indicator: Neutral. This is a routine, planned transaction with no notable signaling power.

Additional Context

Transaction Notes

• Special Circumstances: The sale was made pursuant to a Rule 10b5-1 trading plan adopted on July 23, 2024. A separate transaction on November 15, 2025, involved the disposition of 6,347 shares at $3.25 each to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). This is a non-market transaction and is common practice.